IRF4

(redirected from MUM1)

IRF4

A gene on chromosome 6p25-p23 that encodes a member of the interferon regulatory transcription factor (IRF) family, which is characterised by an unique tryptophan pentad-repeat DNA-binding domain. IRF4 is lymphocyte specific and negatively regulates Toll-like-receptor (TLR)-signalling, which is central to activating the innate and adaptive immune systems.

Molecular pathology
A chromosomal translocation involving IRF4 and the IgH locus, t(6;14)(p25;q32), has been linked to myeloma.
Mentioned in ?
References in periodicals archive ?
Immunophenotypic analysis revealed that the tumor was positive for CD20, CD79a, BCL2, BCL6, and MUM1.
65) As mentioned, apart from CD10, 2 additional antigens, BCL6 and MUM1, are included in the designation of GC versus non-GC phenotypes of DLBCL in the Hans (29) algorithm with approximately 80% concordance with gene expression profiling.
La expresion positiva de CD79a y MUM1 y negativa de PAX5, CD3 y lisozima concluyeron el diagnostico de linfoma B inmunoblastico.
Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45) and MelanA.
10] Immunophenotypic plasmablastic cells are positive for CD138, CD38, and MUM1.
Along with the diagnosis, there is an increasing need to evaluate prognostic markers like CD10, BCL2, BCL6 and MUM1 to subcategorize DLBCL into Germinal Centre (GC) type or Activated B Cell (ABC) type as they have different survival rates.
Se han disenado varios algoritmos para hacerlo, uno es el protocolo de Hans y colaboradores (8), basado en la expresion de CD10, Bcl-6 y MUM1, para diferenciar en los perfiles el origen en centro germinal (GCB) o diferente al centro germinal (no-GCB).
Few studies have reported the use of immunohistochemical expression of CD10, Bcl-6, and/or MUM1 to classify cases of DLBCL into GC and non-GC subtypes in ARL patients.
A partir de los hallazgos en expresion diferencial de mRNA de varios marcadores se ha comprobado que los LDDCG se pueden clasificar en dos grupos de pronostico: los de centro germinal y los que no corresponden a centro germinal con base en la deteccion por immunohistoquimica de CD10, bcl-6 y MUM1 (6).
In addition, there is greater variability in the nuclear size and morphology, and most cases of BL in the HIV setting express MUM1.
Of note, the most widely used immunohistochemistry method is the Hans algorithm, which is based on a few markers, that is, 2 GCB markers, CD10 and BCL-6, and 1 activation marker, MUM1.